Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT
APPROVAL FOR UNIPATH ELECTRONIC BRONCHOSCOPIC SURGICAL ROBOTIC SYSTEM BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors the updates on the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Group's self-developed bronchoscopic surgical robot 獨道® UniPath™ Electronic Bronchoscopic Surgical Robotic System ("**UniPath**"), has been formally approved by the National Medical Products Administration of China (the "**NMPA**").

IMPACT ON THE COMPANY

The approval of UniPath by NMPA is a milestone breakthrough for the Group in leading the development of technologies and applications in the global surgical robot industry, and also signifies the systematic full coverage in the key technological pathway of minimally invasive and non-invasive diagnosis and treatment. As to this point, the number of the Group's approved products in the field of surgical robots has increased to seven, becoming the first and only enterprise in the world to realise the approval and commercialisation of full-spectrum products across "five major and fast-growing surgical specialties" in the field of surgical robots. A domestic surgical robot ecosystem with systematic innovation as the core and platformised capability output as the support, featuring systematic integrity, technological depth and sustainable evolution capability, is being built by the Group and is accelerating into shape and entering the stage of large-scale development.

ABOUT UNIPATH

The newly approved UniPath is a non-invasive natural orifice transluminal robotic platform. The system features an ultra-smooth, ultra-thin snake-shaped robotic catheter, which can access hard-to-reach and narrow lesions through human's natural orifice without making any wound on the body. It holds significant importance for the early diagnosis and treatment of early-stage lesions such as pulmonary micronodules.

As a typical representative of natural orifice transluminal surgical robots, bronchoscopic surgical robots are regarded as a key technological pathway driving the evolution of minimally invasive surgery toward "less trauma and no external incisions", and are also one of the fastest-growing intelligent minimally invasive diagnostic and therapeutic platforms in the field of respiratory intervention in recent years.

UniPath integrates key technologies such as robotic precision control, thin and flexible catheter navigation, intelligent path planning and closed-loop control at the system level, building a total solution for complex pulmonary anatomical environments. It focuses on four core capabilities such as "full lung accessibility, full visualisation throughout, precise alignment and stable operation". Through the multi-layered collaboration of instruments, navigation, imaging and control, the accessibility to the bronchioles and deep lung segments is effectively enhanced, and it supports the higher-certainty access, puncture and ablation operations of deep and peripheral small pulmonary lesions under dynamic breathing conditions, continuously expanding the clinical application boundaries of bronchoscopic interventions.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 24 December 2025

As at the date of this announcement, the executive directors of the Company are Dr. Chao He and Mr. Yu Liu, the non-executive directors of the Company are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors of the Company are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.